CLPT Earnings Prediction
The chart below shows how CLPT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLPT sees a +7.13% change in stock price 10 days leading up to the earnings, and a +7.68% change 10 days following the report. On the earnings day itself, the stock moves by -1.91%. This data can give you a slight idea of what to expect for the next quarter's release.
CLPT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
8.12M
40.96%
3.36%
Gross Margin
59.68%
5.07%
-5.99%
Operating Margin
-63.68%
-25.07%
5.59%
Net Margin
-61.24%
-26.62%
9.16%
EPS
-0.18
-10.00%
12.50%
No Data Available
CLPT Earnings Analysis
ClearPoint Neuro, Inc. Common Stock Corporation (CLPT.O) Earnings Conference Call
Positive
Record Revenue Achievement: The company reported a record revenue of $8.1 million for the third quarter of 2024, representing a 41% growth compared to $5.8 million in the same period last year.
Biologics Revenue Surge: Biologics and Drug Delivery revenue grew by 27% or $4.4 million in the third quarter, up from $3.5 million in 2023, driven by a 353% increase in product revenue.
Neurosurgery Revenue Surge: Neurosurgery Navigation and Therapy revenue increased by 49% to $2.9 million for the third quarter, fueled by new account activations and expanded product introductions.
Capital Equipment Revenue Surge: Capital Equipment and Software revenue increased by 133% to $0.8 million in the third quarter from $0.4 million in the same period in 2023, reflecting strong demand.
Gross Margin Improvement: Gross margin for the third quarter of 2024 was 60%, compared to 57% for the same period last year, primarily due to increased volume and lower costs.
Negative
Quarterly Revenue Growth: Total revenue was $8.1 million for the three months ended September 30, 2024, compared to $5.8 million for the three months ended September 30, 2023, which represents an acceleration to 41% growth versus the third quarter of 2023 and the fourth quarter in a row of growth above 30%.
R&D Cost Increase: Research and development costs were $3.3 million for the three months ended September 30, 2024, compared to $2.4 million for the same period in 2023, an increase of $0.9 million or 36%.
Sales and Marketing Expense Increase: Sales and marketing expenses were $3.5 million for the third quarter compared to $2.8 million for the same period in 2023, an increase of $0.7 million or 25%.
Administrative Expense Increase: General and administrative expenses were $3.2 million for the third quarter compared to $2.9 million for the same period in 2023, an increase of $0.3 million or 9%.
Cash Position Decline: As of September 30, 2024, we held cash and cash equivalents of $21.6 million compared to $32.8 million as of June 30, 2024.
CLPT FAQs
How does CLPT typically perform around its earnings report dates?
Is ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CLPT Earning Call Sentiment
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CLPT.O
-0.84%Positive
The earnings call showed strong financial performance with significant revenue growth across all segments, improved gross margins, and reduced operational cash burn. The increased revenue guidance and strategic partnerships add to the positive sentiment. However, management's reluctance to provide specific 2025 guidance and regulatory risks pose some uncertainties. Despite these, the overall sentiment remains positive, driven by strong growth pillars and market expansion efforts.